Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency‐mediated mitochondrial dysregulation
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.27979
Abstract: Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has significant potential for application in the treatment of urothelial carcinoma (URCa) of the bladder. Previous studies have shown that regulation of the AMP‐activated serine/threonine protein kinase… read more here.
Keywords: growth inhibition; urothelial carcinoma; urca cells; lkb1 deficiency ... See more keywords